- 专利标题: Biomarker directed multi-target immunotherapy
-
申请号: US15119661申请日: 2015-02-18
-
公开(公告)号: US10143734B2公开(公告)日: 2018-12-04
- 发明人: Robert Petit
- 申请人: Advaxis, Inc.
- 申请人地址: US NJ Princeton
- 专利权人: Advaxis, Inc.
- 当前专利权人: Advaxis, Inc.
- 当前专利权人地址: US NJ Princeton
- 代理机构: Alston & Bird LLP
- 国际申请: PCT/US2015/016348 WO 20150218
- 国际公布: WO2015/126921 WO 20150827
- 主分类号: A61K39/02
- IPC分类号: A61K39/02 ; C12Q1/6886 ; G01N33/574 ; A61K45/06 ; A61K39/00 ; C07K14/195
摘要:
This invention provides methods and compositions for using evaluating biomarker expression in a disease and providing a multi-targeted Listeria-based immunotherapeutic approach against said disease. In a related aspect, the invention relates to a method of treating a disease in a subject, the method comprising the steps of: a. obtaining a biological sample from said subject; b. evaluating the expression of a predetermined number of biomarkers in said biological sample; c. administering to said subject a composition comprising a recombinant Listeria strain, said strain comprising a nucleic acid sequence encoding at least one fusion protein, wherein said fusion protein comprises a biomarker identified in said biological sample, wherein said biomarker is associated with said disease, wherein said biomarker is fused to a PEST-containing polypeptide, and wherein each fusion protein within said Listeria comprises a different biomarker, thereby treating said disease in said subject.
公开/授权文献
- US20170106072A1 Biomarker Directed Multi-Target Immunotherapy 公开/授权日:2017-04-20
信息查询